AbbVie (ABBV) Operating Income (2012 - 2026)
AbbVie (ABBV) reported Operating Income of $4.0 billion for Q1 2026, up 6.88% year-over-year from $3.7 billion in Q1 2025, and down 12.19% quarter-over-quarter from $4.5 billion in Q4 2025.
AbbVie (ABBV) Operating Income (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Operating Income data on file, last reported at $4.0 billion in Q1 2026.
- Operating Income for Q1 2026 came in at $4.0 billion, up 6.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.3 billion (up 52.22% YoY), and the FY2025 annual result was $15.1 billion, up 64.99% from the prior year.
- Operating Income eased to $4.0 billion in Q1 2026 per ABBV's latest filing, from $4.5 billion in the prior quarter.
- Over five years, Operating Income peaked at $5.5 billion in Q4 2022 and troughed at -$1.5 billion in Q4 2024.
- A 5-year average of $3.5 billion and a median of $3.8 billion in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income sank 146.64% in 2024, then soared 404.97% in 2025.
- A 5-year view of Operating Income shows it stood at $5.5 billion in 2022, then sank by 41.93% to $3.2 billion in 2023, then slumped by 146.64% to -$1.5 billion in 2024, then soared by 404.97% to $4.5 billion in 2025, then fell by 12.19% to $4.0 billion in 2026.
- Business Quant data shows ABBV's Operating Income at $4.0 billion in Q1 2026, $4.5 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -182.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.99 Bn |
| Dec 31, 2025 | 4.54 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 4.89 Bn |
| Mar 31, 2025 | 3.73 Bn |
| Dec 31, 2024 | -1.49 Bn |
| Sep 30, 2024 | 3.83 Bn |
| Jun 30, 2024 | 4.00 Bn |
| Mar 31, 2024 | 2.80 Bn |
| Dec 31, 2023 | 3.20 Bn |
| Sep 30, 2023 | 2.28 Bn |
| Jun 30, 2023 | 4.51 Bn |
| Mar 31, 2023 | 2.77 Bn |
| Dec 31, 2022 | 5.50 Bn |
| Sep 30, 2022 | 4.60 Bn |
| Jun 30, 2022 | 3.30 Bn |
| Mar 31, 2022 | 4.72 Bn |
| Dec 31, 2021 | 5.07 Bn |
| Sep 30, 2021 | 4.31 Bn |
| Jun 30, 2021 | 4.44 Bn |